Prevention effect of fenofibrate/pioglitazone in obese diabetic patients

Not Applicable

• Conditions: Nutritional, Metabolic, Endocrine; T2DM, obesity

• Registration Number: PACTR201407000856135
• Lead Sponsor: faculty of pharmacy, ain shams university

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-07-16
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Subjects suffering from type 2 DM for at least 5 years and body mass index (BMI) > 30 for diabetic patients groups, Over 50 years of age for females, No definite indication for receiving, and no contraindication to receiving fenofibrate (and pioglitazone for Group 2) in addition to their existing therapy.

Exclusion Criteria

Subjects with type 1 diabetes, Allergy to any fibrate drugs, Allergy or contraindication for pioglitazone drug (for Group 2), History of pancreatitis or pulmonary embolism or deep venous thrombosis, Use of any other investigational agents in last 8 weeks, Unstable condition including recent MI, heart failure, prior organ transplant, severe renal or liver dysfunction, history of myositis or untreated hypothyroidism, Pregnancy and lactation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
serum sirtuin 1 level

Secondary Outcome Measures

Name	Time	Method
serum fetuin A level